2013, Number 6
<< Back Next >>
Med Int Mex 2013; 29 (6)
Needed the Creation of a Drug-Surveillance Center Specialized in Antiretroviral Agents in Mexico
Estrada-Hernández LO, Ríos-Smith MD, Téllez-Santoyo A
Language: Spanish
References: 23
Page: 612-621
PDF size: 552.23 Kb.
ABSTRACT
Toxicity of antiretroviral treatment is an important situation
that we face every day, as evidenced by its high incidence
and for its acute and long-term consequences, which may
be irreversible or fatal. Its incidence is inferred high but the
true extent is unknown. It is said that over 90% of patients
retroviral therapy users have experienced any adverse reactions
of varying severity at some point in their life, and it is
influenced by potential drug interactions, the chronicity of
treatment, other comorbidities, changes to retroviral therapy
for any reason, including and most importantly, the same
toxicity (80%) cases, which affects adherence to antiretroviral
therapy. We are not accustomed to reporting of suspected
adverse reactions to drugs in general and especially antiretrovirals,
considering it useless and even punitive trend. However,
all the information is important since physicians have the
responsibility to manage patients with chronic HIV infection
and maintain good quality of life, free of opportunistic infections
and a long survival with minimal effects possible. This
is our great mission.
REFERENCES
Bozzette SA, Ake CF, Tam HK, Chang SW. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-710.
Carr A, et al. A syndrome of lipodystrophy, hyperlipidemia and insulin resistence in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-58.
DAD Study Group, et al. Use of nucleoside reverse, transcriptase inhibitors and risk of myocardial infarction in HIV infected patients enrolled in the DAD study; a multi-cohort collaboration. Lancet 2008;371:1417-1426.
Fischer M, et al. A randomized comparative trial of continued ZDV/LMV of replacement whit TDF dosiproxil fumarate/FTC in EFV-treated HIV-infected individuals. J Acquir Immune Defic Syndr 2009;51:592-568.
Lang S, et al. Impact specific NRTI and PI exposure on the risk of myocardial infarction; a case control study nested within FHDH ANRS CO4 16th Conference on Retroviruses and Opportunistic Infections, Montreal Canada, February 8-11, 2009.
Squires K, et al. Similar efficacy and tolerability of ATZ compared to ATZ7R each in combination con ABC/LMV (ABC/3TC) after initial suppression with ABC/3TC+ATA/r in HIV-1 infected patients: 84 week results of the ARIES trial 5th International AIDS Society Conference on HIV Pathogenesis Treatment and Prevention. Cape Town, South Africa, July 19-22, 2009.
Insight and DAD Study Groups. Strategies for management of anti-retroviral therapy. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarctions in HIV-infected patients. AIDS 2008;22:F17-F24.
Volberding PA. anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis 2004;38:1454-1463.
ASTER, ADE Spontaneous Triggered Event Reporting. http://www.asterstudy.com
British Medical Association, http://www.bmaorg.uk
National Institute for Clinical Excellence, http://www. nice,org.uk
Medicines and Healthcare Products Regulatory Agency, http://www.mhra.gov.uk
Tebas P, et al. Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects whit peripheral lypoatrophy: results of ACTG A 5110. J Antimicrob Chemother 2009;63:998-1005.
Clinical Human Factors Group, http://www.chfg.org
Drug Information Association, http://wwwdiahome.org
European Medicines Agency, http://www.eacpt.eu
European Association for Clinical Pharmacoepidemiology and Pharmacovigilance, http://www.encepp.eu
US Food and Drug Administration, http://www.fda.gov
Global Patient Safety Alerts, http://www.globalpatiensafetyalerts. com
International Organizations Government Agencies, http://www.hmoresearchenetwork.org
International Federation of Association of Pharmaceutical Physicians, http://www.ifapp.org
International Society for Pharmacoepidemiology, http:// wwwpharmacoepi.org
Pharmaceutical information and Pharmacovigilance Association, http://www.pipaonline.org.uk
Full text